Doctors Revision

Cholinesterase Inhibitors: Dementia Pharmacology, Dosing and Safe Monitoring

Text size
On this page

1 Overview

Cholinesterase inhibitors increase acetylcholine at synapses by blocking its breakdown. The class splits into two clinical families: the centrally acting agents used in dementia — donepezil, galantamine and rivastigmine — and the peripherally acting agents used in myasthenia gravis (pyridostigmine, neostigmine), reversal of neuromuscular block and anticholinergic poisoning (physostigmine). In dementia they are symptomatic, modestly effective and never curative: the honest prescribing skill is setting expectations, titrating slowly and managing the cholinergic adverse-effect burden.

Cholinergic neuroeffector junction showing acetylcholine release and metabolism
Acetylcholinesterase in the synaptic cleft hydrolyses acetylcholine within milliseconds. Inhibiting it raises acetylcholine concentration at both central and peripheral cholinergic synapses — the basis of both the benefit and the adverse-effect profile.

2 Learning Objectives

  • Explain the cholinergic hypothesis behind the dementia agents and their symptomatic (not disease-modifying) nature.
  • Compare donepezil, galantamine and rivastigmine — mechanisms, dosing, formulations.
  • Describe the peripheral uses and safety of pyridostigmine, neostigmine and physostigmine.
  • Anticipate adverse effects, drug interactions and perioperative concerns.
  • Counsel patients and caregivers on realistic expectations and adherence.

3 The Rationale in Alzheimer Disease

Alzheimer disease damages the basal forebrain cholinergic system; the degree of cholinergic loss correlates with the severity of cognitive impairment. Cholinesterase inhibitors raise acetylcholine availability at surviving synapses, modestly improving cognition, function and behaviour in mild-to-moderate disease (and severe disease for donepezil/rivastigmine patch). Three honest limitations govern their use: (1) they do not modify the underlying disease — amyloid and tau pathology progress regardless; (2) benefit is a modest delay of decline, typically measured in months, not restoration; (3) efficacy declines as cholinergic neurons are lost. All three central agents have similar efficacy — choice rests on tolerability, formulation and convenience, not potency. Memantine (an NMDA antagonist) is the other mainstay and combines safely with them.

4 The Three Dementia Agents in Detail

Donepezil

A reversible, centrally selective acetylcholinesterase inhibitor (piperidine derivative), well absorbed and once daily. Dosing: 5 mg once daily at night, increase to 10 mg after 4–6 weeks; a 23 mg formulation exists for moderate–severe disease after tolerating 10 mg. The best-tolerated of the three (fewer GI events than rivastigmine in comparative data). Adverse effects: nausea, diarrhoea, insomnia, vivid dreams, muscle cramps, fatigue; rarely dizziness, bradycardia. Give at night to reduce GI upset; insomnia and dreams can be reduced by morning dosing.

Galantamine

A reversible competitive inhibitor with an additional nicotinic receptor allosteric potentiating action (dual mechanism). Dosing: 4 mg twice daily (or 8 mg once-daily ER) titrated every 4 weeks to 12 mg bd / 24 mg ER; slower titration than donepezil and more GI upset. Renal caution (CrCl 9–59 mL/min: max 16 mg/day; avoid below 9). Metabolised by CYP2D6 and CYP3A4 — interacting drugs (fluoxetine, paroxetine, ketoconazole, digoxin) matter.

Rivastigmine

Inhibits both acetylcholinesterase and butyrylcholinesterase; the only agent also indicated for Parkinson disease dementia. Oral: 1.5 mg twice daily with food, titrate by 1.5 mg every ≥4 weeks to 3–6 mg bd (highest GI burden of the three). The transdermal patch (4.6 mg/24 h → 9.5 mg/24 h; up to 13.3 mg/24 h in severe disease) markedly improves GI tolerability and suits patients with poor adherence or swallowing — application-site reactions are the trade-off. May improve gait stability and reduce falls in Parkinson disease.

5 Peripherally Acting Inhibitors

  • Pyridostigmine — myasthenia gravis mainstay (quaternary amine, poor CNS penetration): 60 mg tablets multiple times daily, or 180 mg sustained-release once/twice daily; onset ~30–45 min, duration 3–4 hours. Titrate to symptom control and avoid cholinergic excess (muscarinic: cramps, diarrhoea, bradycardia, secretions; nicotinic: fasciculations → weakness).
  • Neostigmine — injectable, for myasthenic crisis and reversal of non-depolarising neuromuscular block (with glycopyrrolate/atropine to block muscarinic effects); also used for acute colonic pseudo-obstruction (Ogilvie).
  • Physostigmine — a tertiary amine that crosses the blood–brain barrier; IV use is reserved for anticholinergic (atropine-type) toxicity with delirium. Short half-life, narrow index, cholinergic adverse effects — specialist use only.
  • Organophosphates (irreversible inhibitors) — the toxicology side: pesticides and nerve agents cause cholinergic crisis (muscarinic SLUDGE/DUMBBELS syndrome, nicotinic fasciculations and paralysis, CNS effects). Manage with atropine (large repeated doses), pralidoxime (oxime, before ageing), airway support, and red-cell cholinesterase measurement for diagnosis/monitoring.

6 Drug Monographs: Doses, Indications & Safety

Each cholinesterase inhibitor as a full monograph: mechanism → indications → adult dose → paediatric dose → adverse effects → contraindications → interactions → patient advice. Doses are standard teaching doses — confirm against the current Uganda Clinical Guidelines before prescribing.

Donepezil

Scroll the table sideways on a smaller screen.

Donepezil — reversible, centrally selective AChE inhibitor
MechanismReversible inhibition of acetylcholinesterase (selective for the CNS) → ↑ acetylcholine at surviving cholinergic synapses
IndicationsMild, moderate and severe Alzheimer disease; off-label in vascular and other dementias where cholinergic deficit contributes
Adult dose5 mg once daily at night, increase to 10 mg after 4–6 weeks; 23 mg once daily for moderate–severe disease after tolerating 10 mg
Paediatric doseNot established
Adverse effectsNausea, diarrhoea, anorexia, weight loss, insomnia, vivid dreams, muscle cramps, fatigue; bradycardia, syncope, GI bleeding risk
ContraindicationsHypersensitivity to piperidines; caution with sick sinus syndrome, conduction disease, active peptic ulcer, seizures
InteractionsAnticholinergic drugs antagonise its effect; beta-blockers add bradycardia; enzyme inducers (phenytoin, carbamazepine, rifampicin) increase clearance; prolongs succinylcholine; antacids/cholinergics add GI effects
Patient advice / monitoringTake at night; give with food if nausea; expect GI upset for 1–2 weeks at each dose step; report slow pulse, fainting, poor appetite or weight loss; regular pulse and weight checks

Galantamine

Scroll the table sideways on a smaller screen.

Galantamine — reversible AChE inhibitor + nicotinic allosteric potentiator
MechanismReversible competitive AChE inhibition plus allosteric potentiation of presynaptic nicotinic receptors (dual cholinergic action)
IndicationsMild–moderate Alzheimer disease (tablets, oral solution, once-daily ER capsules)
Adult doseStart 4 mg twice daily (or 8 mg ER once daily) with food; increase every ≥4 weeks to 12 mg twice daily / 24 mg ER; take with the morning and evening meals
Paediatric doseNot established
Adverse effectsMore GI upset than donepezil — nausea, vomiting, diarrhoea, anorexia, weight loss; dizziness, headache, bradycardia; rare fainting
ContraindicationsSevere hepatic impairment; renal: max 16 mg/day if CrCl 9–59 mL/min; avoid if <9
InteractionsCYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) and CYP3A4 inhibitors (ketoconazole) raise levels; inducers lower them; additive bradycardia with beta-blockers, digoxin
Patient advice / monitoringTake with food (reduces nausea); the titration is slower than donepezil — don't rush dose steps; report poor appetite, dizziness or fainting; review interacting medicines at each visit

Rivastigmine

Scroll the table sideways on a smaller screen.

Rivastigmine — dual AChE + butyrylcholinesterase inhibitor
MechanismInhibits both acetylcholinesterase and butyrylcholinesterase → broad cholinergic potentiation in brain and periphery
IndicationsAlzheimer disease; Parkinson disease dementia and Lewy body dementia (rivastigmine is the agent with this indication); may improve gait stability and reduce falls in PD
Adult doseOral: 1.5 mg twice daily with food, increase by 1.5 mg every ≥4 weeks to 3–6 mg twice daily. Patch: 4.6 mg/24 h → 9.5 mg/24 h after 4 weeks (13.3 mg/24 h for severe disease)
Paediatric doseNot established
Adverse effectsHighest GI burden of the three (nausea, vomiting, diarrhoea, anorexia, weight loss); patch: application-site reactions but much less GI upset; bradycardia
ContraindicationsAs other cholinesterase inhibitors; caution in hepatic impairment (hepatic metabolism)
Interactionsβ-blockers: additive bradycardia — avoid; anticholinergic antagonism; prolongs succinylcholine; NSAID/peptic ulcer bleeding risk
Patient advice / monitoringTake oral doses with food and titrate slowly; consider the patch when GI upset or adherence limits oral therapy; rotate patch sites daily; report skin reactions, poor appetite or slow pulse

Pyridostigmine (peripheral)

Scroll the table sideways on a smaller screen.

Pyridostigmine — reversible quaternary AChE inhibitor (peripheral)
MechanismReversible AChE inhibition at the neuromuscular junction; quaternary amine → poor CNS penetration
IndicationsMyasthenia gravis (maintenance); sometimes used off-label for postural orthostatic tachycardia
Adult dose60 mg tablet 3–4 times daily (onset 30–45 min, duration 3–4 h); or 180 mg sustained-release once–twice daily (not for acute crisis); titrate to symptoms
Paediatric dose1 mg/kg per dose 4–6 times daily (max 300 mg/day; specialist, e.g. 7 mg/kg/day divided)
Adverse effectsCholinergic excess — muscarinic: cramps, diarrhoea, sweating, salivation, bradycardia; nicotinic: fasciculations then weakness (cholinergic crisis)
ContraindicationsMechanical intestinal or urinary obstruction; caution in asthma, arrhythmias
InteractionsAntibiotics that impair neuromuscular transmission (aminoglycosides, fluoroquinolones, macrolides, telithromycin) can worsen weakness; beta-blockers may aggravate myasthenia; other anticholinergics antagonise
Patient advice / monitoringDose to effect, spaced around symptoms (e.g. before meals to help swallowing); know the difference between under-treatment (weakness) and over-treatment (cramps, diarrhoea, fasciculations); report new antibiotics to the prescriber

Neostigmine (peripheral, injectable)

Scroll the table sideways on a smaller screen.

Neostigmine — reversible quaternary AChE inhibitor, injectable
MechanismSame peripheral AChE inhibition; quaternary amine — does not cross the BBB
IndicationsMyasthenic crisis (injectable bridge); reversal of non-depolarising neuromuscular block after surgery; acute colonic pseudo-obstruction (Ogilvie syndrome)
Adult doseMG crisis: 1–2 mg IM or slow IV every 2–4 hours (with atropine 0.6–1.2 mg to limit muscarinic effects); reversal of block: 0.5–2.5 mg slow IV with glycopyrrolate/atropine
Paediatric dose0.025–0.08 mg/kg IM/IV per dose (specialist, per indication)
Adverse effectsMuscarinic effects (bradycardia, salivation, cramps, diarrhoea) — hence co-prescribed antimuscarinic; fasciculations; weakness in excess
ContraindicationsMechanical GI/urinary obstruction; peritonitis; caution in asthma, arrhythmias
InteractionsAminoglycosides and other neuromuscular-blocking antibiotics antagonise myasthenia treatment; additive bradycardia with beta-blockers
Patient advice / monitoringHospital-administered; monitor pulse and secretions during use; train-of-four monitoring when used for block reversal

Physostigmine (tertiary, CNS-penetrating)

Scroll the table sideways on a smaller screen.

Physostigmine — tertiary-amine AChE inhibitor (crosses the blood–brain barrier)
MechanismReversible AChE inhibition centrally and peripherally; the tertiary amine structure allows CNS penetration
IndicationsAnticholinergic (atropine-type) toxicity with delirium; historical use in glaucoma
Adult dose1–2 mg slow IV over 2 minutes; repeat every 5–20 minutes to effect (max cumulative ~4 mg); cardiac monitoring required; short half-life (~30 min) → repeated dosing or infusion may be needed
Paediatric dose0.02 mg/kg slow IV (max 0.5 mg/min, max cumulative 2 mg) — specialist toxicology use
Adverse effectsCholinergic excess — salivation, vomiting, diarrhoea, bradycardia, fasciculations, seizures in overdose; asystole if pushed too fast
ContraindicationsTCA overdose (conduction disease → asystole risk), mechanical obstruction, asthma
InteractionsAdditive cholinergics; antagonises anticholinergic drugs (by design)
Patient advice / monitoringResuscitation setting only; continuous cardiac monitoring; reassess mental status after each dose — awakening confirms anticholinergic toxicity

7 Comparison Table

Scroll the table sideways on a smaller screen.

DrugSelectivity / extra actionDosingNotes
DonepezilAChE-selective, reversible5 mg nocte → 10 mg after 4–6 wksBest tolerated; once daily; 23 mg for severe disease
GalantamineReversible AChE inhibitor + nicotinic allosteric potentiator4 mg bd (8 mg ER od) → 12 mg bd (24 mg ER)Dual mechanism; CYP2D6/3A4 interactions; renal caution
RivastigmineAChE + butyrylcholinesterase inhibitor1.5 mg bd → 3–6 mg bd; patch 4.6–9.5 mg/24 hParkinson dementia; patch = better GI tolerability
PyridostigminePeripheral (quaternary amine)60 mg tds–qid, or 180 mg SR od/bdMyasthenia gravis
NeostigminePeripheral, injectableIV per indicationMG crisis; reversal of non-depolarising block
PhysostigmineCrosses BBB1 mg/mL IV/IMAnticholinergic toxicity only; narrow index

8 Adverse Effects

  • Cholinergic (expected, dose-related) — nausea, vomiting, diarrhoea, anorexia, weight loss are the commonest; abdominal cramps, salivation, sweating, urinary frequency. Manage by slow titration, taking with food (rivastigmine, galantamine), switching to the rivastigmine patch, or dose reduction. Persistent anorexia/weight loss needs review — in a frail elderly patient this can be serious.
  • Cardiovascular — bradycardia, syncope, AV block: vagomimetic effect; caution with sick sinus syndrome, conduction disease and beta-blocker co-prescription (additive bradycardia — avoid with rivastigmine). Check pulse at visits.
  • Neurological — insomnia, vivid dreams (donepezil), headache, dizziness, muscle cramps, tremor, rare seizures; increased gastric acid — GI bleeding risk, caution with NSAIDs and ulcer history.
  • Other — urinary obstruction in prostatism (cholinergic bladder contraction), worsening asthma/COPD in theory (bronchial secretions), patch site reactions.

9 Key Interactions

  • Anticholinergics — mutual antagonism (rivastigmine vs oxybutynin/tolterodine); reconcile deliberately.
  • Beta-blockers — additive bradycardia with rivastigmine; avoid in bradycardia/syncope history.
  • Succinylcholine / neuromuscular blockers — cholinesterase inhibition prolongs succinylcholine effect (enzyme that metabolises it is inhibited); plan anaesthesia accordingly and use quantitative neuromuscular (train-of-four) monitoring.
  • CYP effects — galantamine: fluoxetine/paroxetine/quinidine (2D6), ketoconazole (3A4) raise levels; enzyme inducers (phenytoin, carbamazepine, rifampicin) increase donepezil clearance — a real interaction in patients with epilepsy.
  • Digoxin — galantamine co-administration may raise bradyarrhythmia risk.

10 Monitoring & Honest Counselling

  • Baseline & follow-up — pulse/BP, weight, GI history; review after each dose increase (GI tolerance, appetite, sleep) and every 6 months for ongoing benefit vs burden.
  • Measure benefit objectively — cognition scales (MMSE/MoCA), function and caregiver reports; continue only if there is perceived benefit. Guidelines commonly suggest a trial of 3–6 months then review, tapering and stopping if no clear benefit or poor tolerability.
  • Set expectations — "This medicine may help memory and daily function for a time and slow the worsening; it does not cure or stop the disease." Caregiver education on adherence and adverse effects predicts success better than any dose.
  • Stopping — taper rather than stop abruptly when ceasing; benefit is lost either way but abrupt cessation can unmask behavioural deterioration. An overdose or abrupt withdrawal is not associated with a rebound syndrome, but the patient simply loses the symptomatic gain.

11 Special Situations

  • Parkinson disease dementia / Lewy body dementia — rivastigmine is the agent with this indication; avoid anticholinergics entirely in Lewy body disease (severe sensitivity).
  • Hepatic/renal impairment — galantamine dose-capped in renal impairment; rivastigmine is hepatically metabolised (hepatic caution); donepezil hepatically cleared (moderate impairment: slower titration).
  • Perioperative — inform anaesthesia (succinylcholine prolongation, bradycardia); continue through surgery where possible; patch can bridge nil-by-mouth periods.
  • Cost and access — in settings where only donepezil is available, it is a rational default: cheapest, once daily, best tolerated.

12 Viva & Exam Points

  • Three dementia agents — donepezil, galantamine, rivastigmine; similar efficacy; choice by tolerability/formulation.
  • Dual action — galantamine (AChE inhibition + nicotinic potentiation); rivastigmine (AChE + butyrylcholinesterase).
  • Symptomatic only — modest delay of decline; trial 3–6 months; taper if no benefit.
  • Adverse core — GI (nausea, diarrhoea, anorexia, weight loss), bradycardia/syncope, insomnia/dreams.
  • Interactions — anticholinergic antagonism, beta-blocker bradycardia, succinylcholine prolongation, CYP inducers reduce donepezil.
  • Peripheral agents — pyridostigmine = MG; neostigmine = MG crisis/block reversal; physostigmine = anticholinergic poisoning (crosses BBB).

13 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top